梯瓦制药Teva Pharmaceutical Industries Limited (TEVA) 2014年年度报告「NYSE」.pdf

1、Teva Pharmaceutical Industries LimitedContentsTeva at a Glance 4President and Chief Executive Officers Letter to Shareholders 6Financial Highlights 10Business Overview 12Global Reach 16Leadership 18Stockholder Information 20Teva AtA GlanceFounded in 1901 in Israel by three young pharmacists,Teva tod

2、ay is a global pharmaceutical company that provides essential medicines to people around the world.We are committed to increasing access to high quality healthcare by developing,producing and marketing both generic medicines and specialty medicines.As the worlds leading generic medicines maker with

3、a strong specialty medicines portfolio,we are strategically positioned to benefit from ongoing changes in the global healthcare environment.5Teva at a GlanceDear Shareholders:In order to take a significant leap forward,we must first create a solid foundation from which to drive sustainable profitabl

4、e growth.2014 was that year for Teva,as we established a stable underlying base from which we will grow organically in the coming years,enabling us to continue unlocking the value that Teva offers its shareholders.Looking back at the years achievements,I am proud of the significant and measurable pr

5、ogress we made in pursuit of that goal.Despite flat revenues,we significantly increased our margins in 2014,achieving a 10%rise in non-GAAP operating profit from the previous year.We also improved our net profit and EPS,and generated exceptionally strong cash flow from operations and free cash flow.

6、We returned$1.65 billion of cash to shareholders in 2014,paying out more than$1.15 billion in dividends and purchasing$500 million of our stock.The complete details of our financial performance on a GAAP and non-GAAP basis can be reviewed in our 2014 annual report.These results are the strong outcom